Johnson & Johnson Tops Q2 Estimates

Johnson & Johnson (JNJ) reported Q2 2025 results that surpassed analyst estimates for both revenue, which rose 5.8% to $23.7 billion, and adjusted EPS of $2.77, despite a slight year-over-year decline in adjusted earnings and a decrease in free cash flow. The company's performance was driven by strong sales momentum across its Innovative Medicine and MedTech divisions, bolstered by new product launches and pipeline advancements. Consequently, J&J raised its full-year 2025 sales and adjusted earnings guidance, signaling a more optimistic outlook despite ongoing challenges from patent expiries, higher costs, and tariff impacts.

Analysis

Johnson & Johnson's Q2 2025 performance demonstrates resilient top-line growth despite underlying profitability pressures. The company surpassed consensus estimates with revenue of $23.7 billion, a 5.8% year-over-year increase, and adjusted EPS of $2.77. However, this EPS figure represents a 1.8% decline from the prior year, and free cash flow fell a notable 17.4% to $6.2 billion, signaling margin and cash conversion challenges. Growth was fueled by both the Innovative Medicine (+4.9% sales) and MedTech (+7.3% sales) divisions, with strong contributions from key oncology drugs like DARZALEX and CARVYKTI, as well as the Impella heart pump in MedTech. A critical headwind remains the patent expiry of STELARA, which created an 11.7% drag on Immunology revenue, though this is being actively countered by newer launches and pipeline approvals such as IMAAVY. Despite these pressures, which also include approximately $400 million in tariff costs and weakness in the orthopedics segment, management raised its full-year 2025 guidance for both sales to a midpoint of $93.4 billion and adjusted EPS to $10.68, reflecting confidence in its product pipeline and commercial execution.

Key Decisions for Investors

• The strong revenue beat and, more importantly, the raised full-year guidance for both sales and EPS suggest underlying operational strength, making a case for holding or accumulating positions.
• Investors should closely monitor the company's ability to offset the revenue decline from STELARA's patent loss with the ramp-up of new products like TREMFYA and CARVYKTI, as this is the central strategic challenge.
• While sales are strong, it's crucial to watch for margin pressure from ongoing tariff impacts and the significant 17.4% year-over-year decline in free cash flow, which could affect future capital allocation and valuation if the trend continues.